Ampio rises after positive data on IV treatment for COVID-19

Ampio Pharmaceuticals

09/09/2020 14:41

** Drug developer's shares  AMPE.A  rise 12.86% to 79 cents 
    ** Co reports positive results from an early-stage trial for
Ampion, an intravenous treatment for COVID-19 patients
 urn:newsml:reuters.com:*:nPn3fGtxa
    ** Says Ampion-treated patients showed greater improvement
versus patients treated with standard-of-care, including
anti-viral therapies
    ** Ampion may be effective in interrupting
COVID-19-associated inflammation and improving clinical course
and outcome in patients, says company 
    ** Ampion was safe and well-tolerated with no drug-related
adverse events - co
    ** AMPE stock up ~20% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))